

17 Literatura

- Aekplakom W, Chongsuvivatwong V, Tatsanavivat P, Suriyawongpaisal P. Prevalence of metabolit syndrome defined by the international diabetes Federation and cholesterol education program kriteria among thai adults. *Asia Pac J Public Health*. 2011;23(5):792–800.
- Alberti KG, Zimot P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med*. 2006;23(5):469–480.
- Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. *Arterioscler Thromb Vasc Biol*. 2006;26(10):2200–2207.
- Anděl M. Diabetes mellitus a další poruchy metabolismu. *Galen*, 2001:55–62.
- Anderlová K, Haluzík M. Tuková tkáň a inzulinová rezistence. *Diab Met Endrokrin*. 2005;8(2):87–96.
- Aronson D, Bartha P, Zinder O, Kerner A, Markiewicz W, Avizohar O, Brook GJ, Levy Y. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. *Int J Obes Relat Metab Disord*. 2004;28(5):674–679.
- Ashwell M, Cole TJ, Dixon AK. Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. *Br Med J (Clin Res Ed)*. 1985;290(6483):1692–1694.
- Aekplakom W, Chongsuvivatwong V, Tatsanavivat P, Suriyawongpaisal P. Prevalence of metabolit syndrome defined by the international diabetes Federation and national cholesterol education program kriteria among thai adults. *Asia Pac J Public Health*. 2011, 23(5):792–800.
- Alberti KG, Zimmet P, Shaw J. The metabolit syndrome – a new worldwide definitiv. *Lancet*. 2005, 366(9491):1059–1062.
- Aleksandrova K, Nimptsch K, Pischon T. Obesity and colorectal cancer. *Front Biosci*, 2013,5:61–77.
- Allesi MC, Juhan – Vague I. *Arterioscler., Thromb. Vasc Biol*. 2006, 26:2200.
- Aprahamian TR, Sam F. Adiponectin in cardiovascular inflammation and obesity. *Int J Inflam*. 2011, 376909.
- Ashwell M, Cole TJ, Dixon AK. Obesity: new insight into the anthropometric classification of fat distribution shown by computed tomography. *Br Med J*. 1985,290(6483):1692–1694.
- Balducci S, Zanuso S, Nicolucci A, De Feo P, Cavallo S, Cardelli P, Fallucca S, Alessi E, Fallucca F, Pugliese G; Italian Diabetes Exercise Study (IDES) Investigators. Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in

- subjects with type 2 diabetes mellitus: a randomized controlled trial: the Italian Diabetes and Exercise Study (IDES). *Arch Intern Med.* 2010;170(20):1794–1803.
- Balkau B, Deanfield JE, Després JP, Bassand JP, Fox KA, Smith SC Jr, Barter P, Tan CE, Van Gaal L, Wittchen HU, Massien C, Haffner SM. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. *Circulation.* 2007;116(17):1942–1951.
- Barker DPJ. Fetal and infant origins of adult disease. *British Med J.* 1992;68:141–149.
- Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. *J Clin Invest.* 1987;79(3):790–800.
- Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. *Diabetes Care.* 2000;23(1):57–63.
- Bronský J, Nevoral J, Průša R. Adiponektin – marker inzulinové senzitivity. *Čs. Fyziol.* 2005;54:92–96.
- Callahan ST, Mansfield MJ. Type 2 diabetes mellitus in adolescents. *Curr Opin Pediatr.* 2000;12(4):310–315.
- Capasso I, Esposito E, Pentimalli F, Montella M, Maurea N, D' Aiuto M, Fucito A, Grimaldi M, Cavalcanti E, Esposito G, Brillante G, Lodato S, Pedicini T, D' Aiuto G, Ciliberto G, Giordano A. Homeostasis model assessment to detect insulin resistance and identify patients at high risk of breast cancer development: National Cancer Institute of Naples experience. *J Exp Clin Cancer Res*, 2013, of print.
- Cífková R. Prevence kardiovaskulárních onemocnění v dospělém věku. *Supplementum Cor Vasa.* 2005;47(9):3–14.
- Colberg SR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, Chasan-Taber L, Albright AL, Braun B; American College of Sports Medicine; American Diabetes Association. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. *Diabetes Care.* 2010;33(12):e147–167.
- Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE. Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR γ agonists: a potential mechanism of insulin sensitization. *Endocrinology.* 2002;143(3):998–1007.
- D J Barker. The fetal and infant origins of adult disease. *BMJ.* 1990;17; 301(6761):1111.
- DeFronzo, RA, Tobin, JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol Endocrinol Metab.* 1979;237(3):E214–E223.
- Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. *Curr Opin Lipidol.* 2009;20(3):182–189.

- Dockery DW, Pope CA, Xu X, Spengler JD, Ware JH, Fay ME, Ferris BG Jr, Speizer FE. An association between air pollution and mortality in six U.S. cities. *N Engl J Med.* 1993;329(24):1753–1759.
- Ebina Y, Ellis L, Jarnagin K, Edery M, Graf L, Clauser E, Ou JH, Masiarz F, Kan YW. The human cDNA: the structural basis for hormone-activated transmembrane signaling. *Cell.* 1985;40:747–758.
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) *JAMA.* 2001;285(19):2486–2497.
- Febbraio MA. Gp130 receptor ligands as potential therapeutic targets for obesity. *J Clin Invest.* 2007;117(4):841–849.
- Friedenreich CM, Langley AR, Speidel TP, Lau DC, Courneya KS, Csizmadi I, Magliocco AM, Yasui Y, Cook LS. Case-control study of markers of insulin resistance and endometrial cancer risk. *Endocr Relat Cancer.* 2012;19(6):785–792.
- Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. *Diabetes Care.* 1997;20(7):1087–1092.
- Hagström-Toft E, Bolinder J, Ungerstedt U, Arner P. A circadian rhythm in lipid mobilization which is altered in IDDM. *Diabetologia.* 1997;40(9):1070–1078.
- Haluzik M, Sindelka G, Widimsky J Jr, Prazny M, Zelinka T, Skrha J. Serum leptin levels in patients with primary hyperaldosteronism before and after treatment: relationships to insulin sensitivity. *J Hum Hypertens.* 2002;16(1):41–45.
- Haluzík M. Tuk v organismu. In: Svačina Š. a kol.: *Poruchy metabolismu a výživy.* Praha, Galén, 2010, 310–314.
- Haluzík M, Svačina Š. *Metabolický syndrom a nukleární receptory PPAR.* Praha, Grada, 2005, 35–61.
- Haluzík M. Hormony tukové tkáně. *Postgraduální med.* 2010, 1–11.
- Hamdy O, Porramatikul S, Al-Ozairi E. Metabolic obesity: the paradox between visceral and subcutaneous fat. *Curr Diabetes Rev.* 2006;2(4):367–373.
- Harano Y, Hidaka H, Takatsuki K, Ohgaku S, Haneda M, Motoi S, Kawagoe K, Shigeta Y, Abe H. Glucose, insulin, and somatostatin infusion for the determination of insulin sensitivity in vivo. *Metabolism.* 1978;27(9 Suppl 1):1449–1452.
- Hauner H. Secretory factors from human adipose tissue and their functional role. *Proc Nutr Soc.* 2005;64(2):163–169.
- Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. *Proc Natl Acad Sci U S A.* 2005;102(30):10610–10615.
- Himsworth HP, Kerr RB. Insulin sensitive and insulin insensitive type of diabetes mellitus. *Clin Sci.* 1939;4:119–152.
- Horáková D., Pastucha D., Stejskal D., Kollárová H., Azeem K., Janout V. Adipocyte fatty acid binding protein and C-reactive protein levels as indicators of insulin resistance development. *Biomed Pap Fac Univ Palacky Olomouc Czech Rep.* 2011,155(4):241–246.

- Hrnčiar J. Endokrinné choroby a hormonálne metabolické rizikové faktory ischemickej choroby srdca, Syndrom X-5H. EPP, Žilina, 1997.
- Jansson PA, Larsson A, Lönnroth PN. Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus. *Eur J Clin Invest.* 1998;28(10):813–818.
- Jansson PA. Endothelial dysfunction in insulin resistance and type 2 diabetes. *J Intern Med.* 2007;262(2):173–183.
- Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, Yu D, Paul G, Holman RR, Zinman B; Diabetes Outcome Progression Trial (ADOPT) Study Group. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care.* 2010;33(1):177–183.
- Kalant D, Maslowska M, Scantlebury T, Wang H, Cianflone K: Control of lipogenesis in adipose tissue and the role of Acylation Stimulating Protein. *Canadian Journal of Diabetes.* 2003;27:154–171.
- Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Arch Intern Med.* 1989;149(7):1514–1520.
- Karpe F, Fielding BA, Ilic V, Humphreys SM, Frayn KN. Monitoring adipose tissue blood flow in man: a comparison between the (133)xenon washout method and microdialysis. *Int J Obes Relat Metab Disord.* 2002;26(1):1–5.
- Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab.* 2000;85(7):2402–2410.
- Kersten S. The oral rehabilitation of a female bulimia patient. A case report. *Schweiz Monatsschr Zahnmed.* 2000;110(2):128–141.
- Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Blüher M, Unger T, Wolf AM, Knippschild U, Hombach V, Marx N. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. *Arterioscler Thromb Vasc Biol.* 2008;28(7):1304–1310.
- Konradi AO, Rotar OP, Korostovtseva LS, Ivanenko VV, Solntcev VN, Anokhin SB, Bart VA, Shyakhto EV. Prevalence of metabolit syndrome components in a population of bank employees from st. Petersburg, Russia. *Metab Syndr Relat Disord.* 2011;9(5):337–343.
- Kuh D, Shlomo YB. *A Life Course Approach to Chronic Diseases Epidemiology.* 2nd ed. New York: Oxford University Press; 2004.
- Kusminski CM, McTernan PG, Kumar S. Role of resistin in obesity, insulin resistance and Type II diabetes. *Clin Sci (Lond).* 2005;109(3):243–256.
- Kvapil M. Hypertension and diabetes current views on specific questions. *Vnitr Lek.* 2003;49(12):935–937.
- Le Roith D, Zick Y. Recent advances in our understanding of insulin action and insulin resistance. *Diabetes Care.* 2001;24(3):588–597.

- Li S, Guerin-Deremaux L, Pochat M, Wils D, Reifer C, Miller LE. NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study. *Appl Physiol Nutr Metab.* 2010;35(6):773–782.
- Louie SM, Roberts LS, Nomura DK. Mechanisms linking obesity and cancer. *Biochim Biophys Acta.* 2013;13:1388–1398.
- Mather K, Anderson TJ, Verma S. Insulin action in the vasculature: physiology and pathophysiology. *J Vasc Res.* 2001;38(5):415–422.
- Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ, Baron AD. Repeatability characteristics of simple indices of insulin resistance: implications for research applications. *J Clin Endocrinol Metab.* 2001;86(11):5457–5464.
- Mu N, Zhu Y, Wang Y, Zhang H, Xue F. Insulin resistance: A significant risk factor of endometrial cancer. *Gynecol Oncol.* 2012;125(3):751–757.
- National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III). Washington DC: US Govt. Printing Office 2001, NIH publ. No. 01–3670.
- Neel JV, Weder AB, Julius S. Type II diabetes, essential hypertension, and obesity as “syndromes of impaired genetic homeostasis”: the “thrifty genotype” hypothesis enters the 21st century. *Perspect Biol Med.* 1998;42(1):44–74.
- Nesher R, Cerasi E. Modeling phasic insulin release and time-dependent effects of glucose. *Diabetes.* 2002;51:S53–S59.
- Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, Tack CJ, van Krieken H, Kim SH, Stalenhoef AF, van de Loo FA, Verschueren I, Pulawa L, Akira S, Eckel RH, Dinarello CA, van den Berg W, van der Meer JW. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. *Nat Med.* 2006;12(6):650–656.
- Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. *Arch Intern Med.* 2003;163(4):427–436.
- Patja K, Jousilahti P, Hu G, Valle T, Qiao Q, Tuomilehto J. Effects of smoking, obesity and physical activity on the risk of type 2 diabetes in middle-aged Finnish men and women. *J Intern Med.* 2005;258(4):356–362.
- Perušičová J. *Diabetes mellitus 2. typu.* Galén, Praha, 1996: 99–103.
- Phillips DI. Birth weight and the future development of diabetes. A review of the evidence. *Diabetes Care.* 1998;21 Suppl 2:B150–5.
- Quetelet A. *Anthropometrie. Sur l'homme et le développement de ses facultés.* 1870.
- Quisth V, Enoksson S, Blaak E, Hagström-Toft E, Arner P, Bolinder J. Major differences in noradrenaline action on lipolysis and blood flow rates in skeletal muscle and adipose tissue in vivo. *Diabetologia.* 2005;48(5):946–953.
- Reaven G, Tsao PS. Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? *J Am Coll Cardiol.* 2003;41(6):1044–1047.

- Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes*. 1988;37(12):1595–1607.
- Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mokadam F, Lopez-Jimenez F. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. *Lancet*. 2006;368(9536):666–678.
- Rosen K, Coll ML, Li A, Filmus J. Transforming growth factor- α prevents detachment-induced inhibition of c-Src kinase activity, apoptosis of intestinal epithelial cell. *J Biol Chem*. 2001;276(40):37273–37279.
- Rugulies R. Depression as a predictor for coronary heart disease. a review and meta-analysis. *Am J Prev Med*. 2002;23(1):51–61.
- Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ. Digenic inheritance of severe insulin resistance in a human pedigree. *Nat Genet*. 2002;31(4):379–84. Erratum in: *Nat Genet*. 2002;32(1):211.
- Sharma AM, Bramlage P, Kirch W. Antihypertensive effect of iberesartan and predictors of response in obesity-associated hypertension: a prospective, open-label study. *Clin Drug Investig*. 2005;25(12):765–776.
- Simkhovich BZ, Kleinman MT, Kloner RA. Air pollution and cardiovascular injury epidemiology, toxicology, and mechanisms. *J Am Coll Cardiol*. 2008;52(9):719–726.
- Smith AJ, Sanders MA, Juhlmann BE, Hertzog AV, Bernlohr DA. Mapping of the hormone-sensitive lipase binding site on the adipocyte fatty acid-binding protein. *J Biol Chem*. 2011;286(48):33536–33543.
- Sotorník R. Průtok krve tukovou tkání a metabolický syndrom. *Časopis lékařů českých*. 2010;149(4):155–159.
- Sovová E, Nakládalová M, Kaletová M, Lukl J, Benusová I, Doupalová P. The influence of targeted intervention on the incidence of risk factors of cardiovascular diseases at medical staff. *Vnitr Lek*. 2006;52(1):8–9.
- Sovová E. What is the health status of cardiology health care personnel in 2001? *Vnitr Lek*. 2003;49(7):548–550.
- Spáčil J. Vliv znečištění ovzduší na kardiovaskulární mortalitu. *Časopis lékařů českých*. 2009;148:379–382.
- Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? *Eur J Clin Invest*. 2006;36(9):621–625.
- Sucharda P. Obezita – klasifikace, etiologie a epidemiologie. In: Svačina Š, a kol. *Poruchy metabolismu a výživy*. Praha, Galén, 2010, s. 307–310.
- Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. *Clin Sci (Lond)*. 1996;91(6):679–683.
- Svačina Š. *Metabolický syndrom*. Praha, Triton, 2006, 22–42, 243–250.
- Svačina Š. *Obezita a diabetes*. Praha, Maxdorf, 2000, 25–32.
- Svačina Š. *Poruchy metabolismu a výživy*. Galén, 2010: 227–241.

- Škop V, Kontrová K, Zídková J, Zídek V. Adipocytokiny-nedávno objevené hormony tukové tkáně. *Chem. Listy*. 2009;103:187–192.
- Škrha J. *Diabetologie*. Praha, Galen, 2009, 95–110.
- Škrha J. Diabetes mellitus 2. typu jako subklinický zánět. *Časopis lékařů českých*. 2010;149(6):277–280.
- Tada N. Dietary therapy for prevention and treatment of atherosclerosis from the perspective of anti-inflammation. *Nihon Rinsho*. 2011;69(1):110–118.
- Thorand B, Baumert J, Chambless L, Meisinger C, Kolb H, Döring A, Löwel H, Koenig W; MONICA/KORA Study Group. Elevated markers of endothelial dysfunction predict type 2 diabetes mellitus in middle-aged men and women from the general population. *Arterioscler Thromb Vasc Biol*. 2006;26(2):398–405.
- Toye A, Gauguier D. Genetics and functional genomics of type 2 diabetes mellitus. *Genome Biol*. 2003;4(12):241.
- Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med*. 2001;344(18):1343–1350.
- Vaidya VA, Duman RS. Depression-emerging insights from neurobiology. *Br Med Bull*. 2001;57:61–79.
- Vaňková M, Lukášová P, Bradnová O, Včelák J, Dvořáková K, Bendlová B. Vztah sekrece a působení inzulínu – studium genetické determinace. *Časopis lékařů českých*. 2010;149(11):526–532.
- Wang Y, Lam KS, Yau MH, Xu A. Post-translational modifications of adiponectin: mechanisms and functional implications. *Biochem J*. 2008;409(3):623–633.
- World Health Organization. Definition, Diagnosis and Classification of Diabetes mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus (Department of Noncommunicable Disease Surveillance, Geneva, 1999).
- Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. *Nature*. 2003 Jun 12;423(6941):762–9. Erratum in: *Nature*. 2004;431(7012):1123.
- Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. *Am J Physiol Endocrinol Metab*. 2006;290(6):E1253–61.
- Zeman M, Jiráček R, Žák A, Jáchymová M, Vecka M, Tvrzická E, Staňková B, Dušejovská M. Metabolický syndrom a deprese – klinické vztahy. *Časopis lékařů českých*. 2008;147(2):75–80.